Date: 2013-06-12
Type of information: Development agreement
Compound: novel class of non-psychotropic cannabinoids
Company: Aphios (USA) VivaCell Biotechnology (USA)
Therapeutic area: Autoimmune diseases - CNS diseases - Neurodegenerative diseases
Type agreement: R&D
development
commercialisation
Action mechanism:
Disease: multiple sclerosis, other neurodegenerative diseases of the central nervous system
Details: * On June 12, 2013, Aphios Corporation has announced that it has entered into joint Research Collaboration and Commercialization Agreements with VivaCell Biotechnology España S.L., Cordoba, Spain to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system (CNS). Recently, researchers at the University of Córdoba and Cajal Institute (Spain) in collaboration with VivaCell Biotechnology, discovered a novel class of non-psychotropic cannabinoids that has multiple activities on key molecular targets involved in neuroinflammatory and neurodegenerative diseases, with very positive in vitro and in vivo data (US and International Patents Pending). Dr. Eduardo Muñoz, Chief Scientific Officer of VivaCell states, \"In vitro experiments have demonstrated that these compounds activate the PPARy pathway and bind to CB2 receptor showing both anti-inflammatory and neuroprotective activities. In vivo experiments have shown that they cross the blood brain barrier and inhibit neuroinflammation in well-defined animal models of multiple sclerosis and Huntington\'s disease.\"
Aphios and VivaCell have executed research and commercialization agreements to develop these drug candidates through preclinical studies, clinical development and commercialization in the United States and Europe.
Financial terms:
Latest news:
